David Kideckel

David Kideckel, Ph.D., M.B.A., has been the Senior Vice President, Head of Corporate Development & Strategic Alliances at IntelGenx Corp. since March 2023. Dr. Kideckel brings over 15 years of business development, advisory, and capital markets experience to IntelGenx. In 2021, he founded the Kideckel Advisory Group Inc., where he advised growth-oriented companies on business and corporate development, capital markets, and overall strategic initiatives. Prior to that and in 2017, Dr. Kideckel was recruited from industry to capital markets to build healthcare and life sciences equity research franchises, most recently serving as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets Inc. His industry and business development experience spans several senior healthcare and biotechnology roles, including at Alexion Pharmaceuticals, Inc. (acquired by AstraZeneca plc), the world leader in rare diseases.

Dr. Kideckel holds a Ph.D. in Neuroscience & Statistics from the University of Toronto’s Institute of Medical Science and an M.B.A. from the University of Toronto’s Rotman School of Management, where he was a Canadian Institutes of Health Research Science to Business Award recipient.